Letters

We read with great interest Simon Mitton’s article “We Are Publishing Too Many Conference Proceedings” (The Scientist, Feb. 20, 1989, page 9). The author has to be congratulated on his analysis of the situation. No doubt., those in the publication business would agree that proceedings of conferences of marginal interest with numerous uninvited, often unrelated, and frequently unreviewed papers have. spoiled the name “Proceedings,” giving it the connotation of a sec

Written byCraig Sinclair
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

We read with great interest Simon Mitton’s article “We Are Publishing Too Many Conference Proceedings” (The Scientist, Feb. 20, 1989, page 9). The author has to be congratulated on his analysis of the situation. No doubt., those in the publication business would agree that proceedings of conferences of marginal interest with numerous uninvited, often unrelated, and frequently unreviewed papers have. spoiled the name “Proceedings,” giving it the connotation of a second-class publication irrelevant to the advancement of science.

In fact, we understand that some librarians are told by their supervisors to delete systematically and indiscriminately all proceedings volumes from the lists of potential acquisitions, thereby decreasing the dissemination of those proceedings that genuinely contribute to the free communication of science.

The problem starts with the quality of the conference organizer and the approach he or she is taking in putting the meeting program together. A “Call for Papers” may be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies